RESEARCH
intensified case-finding initiatives, earlier diagnosis of HIV, and accelerated entry into care. [4] While there is evidence of improvements in HIV diagnosis and access to ART among children, [5, 6] retention of children in HIV care remains a challenge.
Horstmann et al. [7] define retention in care as 'the regular engagement in long-term clinical care of HIV-infected individuals' . Retention in care is associated with virological control and survival among infected children. [7] However, significant drop-offs are observed along the HIV care continuum in many high HIV prevalence settings. [8] Evidence from cohort studies suggests that loss to follow-up (LTFU) rates are higher in children and adolescents compared with adults in HIV care. [9] [10] [11] [12] Contributing factors include high mobility of mother-child pairs between facilities and weak systems for tracing and linkage among children. A systematic review of retention outcomes of children in the first year of ART in resourcelimited settings reported that younger age (<1 year) was associated with poorer retention among children in HIV care. [13] Similar findings were described in a report of birth HIV diagnosis with ART initiation within the first month of life at a single site in SA. [14] These findings have serious policy implications for SA, where current guidelines recommend birth testing for all HIV-exposed children. [15] Previously, the national prevention of mother-to-child transmission (PMTCT) guidelines recommended routine HIV PCR testing at 6 weeks of age for HIV-exposed children. The guidelines were revised in June 2015, recommending universal HIV PCR testing at birth for HIVexposed neonates, followed by repeat tests at 10 weeks and 6 weeks after cessation of breastfeeding for children with previous negative results. [15] At the same time, a second PCR test on a second blood sample replaced a baseline HIV viral load (VL) test as confirmation of HIV-positive status. HIV enzyme-linked immunosorbent assay tests are used to confirm positive HIV PCR tests if the child is ≥18 months old. The guidelines further recommend a VL 6 months after ART initiation to monitor treatment response. If the VL is <50 copies/mL, a VL is repeated after 12 months; if the VL is 50 -1 000 copies/mL, a VL is repeated in 6 months; and if the VL is >1 000 copies/mL, a repeat VL should be performed in 2 months. [15] However, interpretation and implementation of guidelines is not uniform across or within the nine provinces of SA.
In recent years, complexities in early infant diagnosis have emerged as PMTCT programmes have evolved to include increased number and duration of ART drugs for mothers and infants. This change has resulted in an increase in indeterminate and discordant HIV PCR and VL results that complicate making a definitive diagnosis of HIV in children. [16] [17] [18] Longitudinal cohort monitoring of HIV-infected children receiving HIV care is crucial for evaluating programme performance and adapting interventions to reduce gaps along the HIV care continuum. The National Department of Health uses Tier.net, an electronic patient management system for HIV-infected patients accessing HIV treatment in the public sector in SA. However, Tier.net does not yet provide national coverage and relies on data being captured at healthcare facility level after the patient visit. In contrast, laboratory data are captured at local laboratory level on receipt of samples from multiple healthcare facilities, and data capture is a prerequisite before testing can occur. The ratio of healthcare facilities to local laboratories in SA is >10:1. Larger numbers of patients therefore have their data captured by fewer data capturers at laboratory v. facility level, resulting in a more efficient recording system within the laboratory network.
Objectives
Using a nationally representative routine laboratory HIV test database, to monitor diagnosis, retention in care and VL suppression rates of children testing HIV PCR-positive in two districts in SA. HIV-related tests (VL, HIV enzyme-linked immunosorbent assay (ELISA) and CD4+ counts) from the CDW were documented longitudinally for each child for ≥13 months after the initial positive PCR test, using both an automated patient-linking algorithm and a manual search of the laboratory information system (LIS) and the CDW for laboratory test results. Test sets were linked to a patient if two or more demographics (surname, name, date of birth and folder number) matched exactly. Among neonates, first names and facilities were expected to differ between the birth HIV PCR (performed at <7 days of life) and follow-up tests, because many neonates do not have first names at birth and the majority of mother-child pairs are down-referred to a different health facility for routine care after delivery.
Methods
Data analysis was censored at LTFU or end of follow-up on 31 May 2017. Programmatic indicators evaluated included: • Age at HIV diagnosis. Age at first positive HIV PCR result from the LIS and CDW. • Birth testing coverage. Number of birth HIV PCR tests registered during the study period divided by the estimated number of HIVexposed infants born. The latter was calculated by multiplying live births registered per district (Statistics South Africa, 2015 [19] ) by district antenatal HIV seroprevalence rates (2015 National Antenatal Sentinel HIV & Syphilis Survey Report [20] ). • Timing of HIV transmission, as defined in Table 1 . 
Results uMkhanyakude District (rural), KwaZulu-Natal
A total of 94 children tested HIV PCRpositive during the study period, out of an estimated annual number of 7 018 HIVexposed infants with birth testing coverage of 83.2%. The median age at first positive PCR test was 3.6 months (IQR 1.4 -7.1) ( . 1A ). Of these, 25 (83.3%) had an HIV VL performed and 15 (60.0%) had a VL <1 000 copies/mL. Twenty-two children (23.0%) who were retained in care at 6 months were retained at 12 months.
Tshwane District (urban), Gauteng
A total of 304 children tested HIV PCR-positive during the study period, out of an estimated annual number of HIV-exposed infants of 14 157 with birth testing coverage of 80.3%. The median age at first positive PCR test was 2.3 months (IQR 0.1 -6.7). Almost one-third of infections were confirmed as in utero, with 30.3% of infants having a late diagnosis after 3 months of age (Table 2 ). Of the 304 children with a positive PCR test, 99 (32.6%) were retained in care at the end of follow-up, although 41 of them had missed their 6-month blood tests. Of those retained in care, 28 (28.3%) had a VL <1 000 copies/mL. Two hundred and eighteen children (71.7%) were presumed to have had a confirmed HIV diagnosis after their initial positive PCR result ( Table 2 , Fig. 1B ). Of these, 193 children (88.5%) had a confirmatory HIV test. Total follow-up time was 1 562.8 person-months, with an overall LTFU rate of 135 per 1 000 person-months, significantly higher than the rate in uMkhanyakude (p=0.01). Children with positive PCR results at birth had lower LTFU rates than children diagnosed at older ages. The LTFU rate was 126 per 1 000 personmonths, compared with 130 and 145 per 1 000 person-months in children first diagnosed with HIV at ages 7 days -≤3 months RESEARCH and >3 months, respectively (log-rank p-value <0.001). As age at first positive PCR test increased, the median time to presumed confirmatory testing of a positive PCR result decreased (p=0.003) ( Table 2) . Of 160 children (73.4%) who were presumed to have received HIV confirmatory testing but were LTFU at 6 months, 84 (52.5%) had no further test records, but 76 (47.5%) had additional HIVrelated tests within 3 months, indicating a second visit for HIVrelated care after the first positive PCR test. Only 58 children (19.1%) were retained in care at 6 months. Of these, 50 (86.2%) had an HIV VL performed and 24 (48.0%) had a VL <1 000 copies/mL. Forty-three children (14.1%) who were retained in care at 6 months were retained at 12 months.
Intervals between the 6-month VL and the subsequent VL test were measured to assess conformity with VL guidelines ( Table 3) . Regardless of the 6-month VL result, the median time to a subsequent VL test was longer in uMkhanyakude than Tshwane. Children with VL ≥1 000 copies/mL at 6 months returned for their VL at a median of 7.3 months in uMkhanyakude and 6.6 months in Tshwane, instead of the recommended 2 months as per the guidelines. Fig. 1C depicts the HIV treatment cascade constructed using laboratory HIV test data supplemented by clinical data for Tshwane. The clinical databases documented 41.8% of the Tshwane cohort in comparison with the laboratory database. Supplementing the laboratory with clinical data increased the presumed confirmatory test rate by 9.9% (n=30), and decreased LTFU at 6 and 12 months on ART treatment by 7.8% (n=24) and 7.2% (n=22), respectively. Among children found in the clinical database, 6/127 (4.7%) had died by the end of follow-up.
Discussion
The HIV treatment cascades constructed from laboratory data reveal similar outcomes and critical gaps in both Tshwane and uMkhanyakude. For both districts, overall retention in care at the end of the study period was ~33%, with approximately one-third of HIV-infected children having a VL <1 000 copies/mL. After a first positive HIV PCR test, ~75% of children were presumed to have received confirmatory HIV testing. Alarmingly, within the next 6 months, ~60 -70% of all children with a first positive PCR result were LTFU and only ~50 -60% of those retained achieved a VL <1 000 copies/mL at 6 months after ART initiation. However, if children remained in care until the first 6-month HIV VL monitoring visit, 73 -74% returned for their subsequent visit, with ~57% achieving a VL <1 000 copies/mL. In spite of similar outcomes in the two districts, the LTFU rates in Tshwane were significantly higher than in uMkhanyakude. Differences may be the result of mobility of urban v. rural infants, particularly where mother-infant pairs return to their rural homes after delivery on account of tradition and cultural norms. [21] The largest gap requiring intervention occurred within 3 months of the first positive HIV PCR test, during which time ~75% of children returned for HIV-related testing at least once (and half of these children returned a second time) before two-thirds were LTFU within 6 months. By virtue of the HIV-related tests performed at the visit after the first positive PCR test, healthcare workers appeared to have recognised that these children were HIV-exposed. More than 80% received a PCR or VL test, but it cannot be ascertained whether the healthcare worker had access to the first positive PCR test result and was performing confirmatory early infant diagnosis (EID) testing, or was repeating a screening test unnecessarily. Additionally, the quality of care received at these visits, such as counselling, support, assessment of ART readiness, ART initiation and tracing for defaulters, requires further scrutiny. An understanding of mothers' experiences at the time of positive PCR result return would also be helpful in understanding the high LTFU rates.
Even with birth testing coverage rates in both districts exceeding 80% in the first year of implementation, more than half (56%) of the infants in uMkhanyakude first tested HIV PCR-positive after 3 months of age, in comparison with 41% of infants in Tshwane. In both districts, infants with a positive PCR test at birth were significantly less likely to be LTFU than infants testing positive at older ages. This is reassuring for a programme that recently introduced birth testing. The 8 -10% of children with a first positive PCR result who were LTFU following discordant PCR and VL results at their return visit should be recognised as being at high risk and monitored closely with follow-up PCR and VL tests to establish a definitive HIV diagnosis.
Approximately 20% of children retained in care at 6 months subsequently had CD4+ but no VL results at these visits. In these instances, either VL and CD4+ monitoring guidelines were not correctly followed, or a specimen for VL could have been submitted by the healthcare worker but not registered by the laboratory, for a variety of reasons. The intervals between VL tests demonstrate that VL monitoring is not performed according to guidelines in high-risk children with VL >1 000 copies/mL. Urgent intervention is warranted to achieve earlier subsequent VL tests in pursuit of virological control. Clarity around the guideline recommendation of repeating a VL after 6 or 12 months if the 6-month VL is <50 copies/mL is required.
A national clinical database that includes laboratory test results is ideal for longitudinal cohort monitoring. Tier.net has the potential to fulfil this function, but even where it is available, it is hampered by incomplete data. Accurate monitoring based on a national laboratory database assumes that HIV monitoring tests are performed as frequently as recommended by guidelines. If not, children retained in clinical care without receiving appropriate HIV testing would be under-represented in the laboratory database. For Tshwane, we demonstrate that 58% of the study participants were absent from Currently it is not possible to comment on deaths using the laboratory cascade, as this metric is not captured in the CDW. However, until data and technical problems involved in making this a reality are resolved, the laboratory database represents the most feasible resource in the medium term for national near-real-time monitoring. This strategy has been used to accurately monitor the national EID programme at a far lower cost than national surveys. [4, 5] In addition, since June 2015, laboratory data have been used to generate Results for Action (RfA) reports that are emailed routinely to PMTCT co-ordinators, facility managers and district clinical specialists to enhance follow-up of HIV PCR-positive children. [22] In the light of findings from the present study, RfA dashboards are currently being developed and will also be made available to the above stakeholders to track children who are lost from care and those in care with unsuppressed VLs. Regarding overall retention in care, similar findings were reported from a cohort of 30 infants initiating ART at a median age of 16 weeks in Johannesburg, SA. Thirty-four percent of HIV-infected infants were retained in care after >1 year of ART. [23] Another study conducted in Cape Town, SA, reported a higher rate of retention, 50% after 2.1 years of ART, in a cohort of infants initiating ART within the first month of life (n=22). [14] We attribute this high rate of retention in care to the fact that a small sample of children was followed up, and consider that the overall retention rates of ~30% in our study sites reflect the complexities of managing neonates and infants in HIV care within programmatic settings. Currently, many health facilities lack robust systems for linking and tracking infants in HIV care. The problem is often compounded by a lack of unique patient identifiers for infants. [24] With name changes being common among infants, tracking linkage into care in this group is often difficult, particularly where mother-child pairs alternate between health facilities for care. [15, 21, [23] [24] [25] In SA, it is common for mother-child pairs to be downreferred to different facilities for primary care after delivery. Mobility of mother-child pairs disrupts co-ordination of care, resulting in patients not linking or remaining in care. Since birth testing is routine practice, it follows that more children are being diagnosed with HIV at very young ages. As a result, facilities require robust systems that can effectively link and track this population while in care. The use of Road to Health booklet identifiers issued with the patient-retained immunisation record at time of birth can go a long way towards achieving this end. [25] Interpretation of findings should take cognisance of the fact that a laboratory database is not equivalent to a clinical longitudinal cohort management system. The laboratory-generated treatment cascade assumes that ART is initiated on all children around the time of the first positive HIV PCR test, which is not the case in practice, particularly for children with discordant HIV confirmatory test results that require further investigation and for those with psychosocial issues and comorbidities. Our findings are limited by the lack of a unique identifier in the NHLS CDW in that the patient-linking algorithm may not have linked all HIV-related tests performed on a particular patient, which could have resulted in under-reporting of retention in care and VL outcomes. Birth HIV PCR tests, associated with poor demographic records, are especially at risk of not being linked to later tests. The latter introduces the potential for overestimating the number of children with a first positive PCR test and age at first diagnosis, and underestimating retention in care. Tshwane is at higher risk of these errors than uMkhanyakude, considering that 30% of the first positive PCR tests were at birth. We cannot exclude the possibility that children with a first positive PCR test result die before accessing care and therefore never gain entry into a clinical HIV treatment database such as Tier. net. Our data focus only on the public healthcare sector; migration between public and private healthcare is not accounted for, and its magnitude is unknown, but it is more likely in urban areas such as Tshwane. This factor may explain the higher LTFU rates noted in Tshwane.
Conclusions
We demonstrate the value of using routine laboratory data as a diagnosis, retention in care and VL suppression monitor for HIVinfected children aged <18 months, from the initial positive HIV PCR test to identify critical gaps in the programme. This approach to longitudinal cohort monitoring is scalable, can be reported in near realtime and is relatively inexpensive to implement, but is compromised by the absence of a unique identifier and lack of clinical data.
In spite of three-quarters of children returning to care after their first positive PCR result in 2015/16, retention in HIV care thereafter was poor and accounted for the largest gap in LTFU. Twenty percent of children in care had no VL monitoring results and VLs >1 000 copies/mL were not actively managed, leaving 40% of children in care at 12 months with a VL ≥1 000 copies/mL. The laboratory database provides an opportunity to begin to improve paediatric HIV services in the country until clinical databases can assume the function of longitudinal cohort monitoring.
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